Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472

The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism

Kopan, R., & Ilagan, M. X. G. (2009) · Cell · doi:10.1016/j.cell.2009.03.045 · Cited by 3,764

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327

MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease

Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286

Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia

Weng, A. P., Ferrando, A. A., Lee, W., Morris, J. P., Silverman, L. B., Sanchez-Irizarry, C., Blacklow, S. C., Look, A. T., & Aster, J. C. (2004) · Science · doi:10.1126/science.1102160 · Cited by 2,706

Notch signalling: a simple pathway becomes complex

Bray, S. J. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2009 · Cited by 2,620

Resolving the fibrotic niche of human liver cirrhosis at single-cell level

Ramachandran, P., Dobie, R., Wilson-Kanamori, J. R., Dora, E. F., Henderson, B. E. P., Luu, N. T., Portman, J. R., Matchett, K. P., Brice, M., Marwick, J. A., et al. (2019) · Nature · doi:10.1038/s41586-019-1631-3 · Cited by 1,784

Fibrosis–a common pathway to organ injury and failure

Rockey, D. C., Bell, P. D., & Hill, J. A. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1300575 · Cited by 1,428

From NASH to HCC: current concepts and future challenges

Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392

PROMO: detection of known transcription regulatory elements using species-tailored searches

Messeguer, X., Escudero, R., Farré, D., Núñez, Ó., Martı́nez, J., & Albà, M. M. (2002) · Bioinformatics · doi:10.1093/bioinformatics/18.2.333 · Cited by 1,371

Discovery of Jatrophane Diterpenoids as JAG1-Notch Signaling Inhibitors for the Treatment of Liver Fibrosis

Zhu, X., Wu, S.-Q., Gan, L., Yang, X., Liao, Y.-L., An, N., Fan, R., Huang, J.-L., Tang, G., Zhang, C., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00883 · Cited by 2

Integrating stress signals—XBP1 as a novel mediator of intercellular crosstalk in non-alcoholic steatohepatitis

Yu, J., & Pajvani, U. B. (2021) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh-22-73 · Cited by 1

TLR4 promotes liver fibrosis in metabolic dysfunction-associated steatohepatitis by a mechanism independent of hepatocytes and inflammatory cellsPreprint

Altvater, E. E., Kojh, D., Huang, R., & Caviglia, J. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.25.678670 · Cited by 2

Notch1 Signalling Is Downregulated by Aerobic Exercise, Leading to Improvement of Hepatic Metabolism in Obese Mice

Gaspar, R. C., Macêdo, A. P. A., Nakandakari, S. C. B. R., Muñoz, V. R., Abud, G. F., Vieira, R. F. L., Neto, I. V. D. S., Pavan, I. C. B., da Silva, L. G. S., Simabuco, F. M., et al. (2025) · Liver International · doi:10.1111/liv.70068 · Cited by 1

Targeting the gut microbiota: the application and prospects of probiotics, fecal microbiota transplantation, and natural products in MASLD

Li, M., Zhai, H., Qiao, L., Wang, Z., Yang, L., Zheng, X., Shi, H., Geng, W., & Wang, J. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1735669 · Cited by 1

Liver-specific sustained activation of the LPS/TLR4/NF-κB pathway: from a gut-liver axis hub to cascading extensions in reproductive and neuroinflammation

Xia, Y., Li, Z., Li, Z., Yan, D., 肖德梅, Xia, Y., Li, J., & Liu, Y. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117486 · Cited by 1

LncRNAs, RNA Therapeutics, and Emerging Technologies in Liver Pathobiology

Anwar, A. A., Jalan‐Sakrikar, N., & Huebert, R. C. (2024) · Seminars in Liver Disease · doi:10.1055/a-2490-1921 · Cited by 1

Targeting Toll-like receptor 4 and microbiota dysregulation: a new frontier in nonalcoholic fatty liver disease management

Kvit, K. B. (2025) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.20.8.2024.1464 · Cited by 1

A novel role of RNase L in the development of nonalcoholic steatohepatitis

Chen, G., Zhao, X., Dankovskyy, M., Ansah-Zame, A., Alghamdi, U. M., Liu, D., Wei, R., Zhao, J., & Zhou, A. (2023) · The FASEB Journal · doi:10.1096/fj.202300621r · Cited by 1

Macrophage ATG16L1: potential candidate for MASH treatment

Yu, J. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0443 · Cited by 1

Tumorigenesis from non-alcoholic steatohepatitis to hepatocellular carcinoma

Yu, J., & Pajvani, U. B. (2022) · Medical Review · doi:10.1515/mr-2022-0043

Papel do exercício físico na regulação da proteína Notch1 em camundongos obesos

Gaspar, R. C. (2021) · doi:10.47749/t/unicamp.2021.1166740

Common molecular basis for MASH and hepatitis C revealed via systems biology approach

Cheng, Y., Song, Z., Liu, Y., Xu, X., Zhang, D., Zou, Y., Liu, L., Zeng, Y., Li, W., Bai, D., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1442221

Toll-Like Receptors, PAMPs, and DAMPs in Hepatotoxicity

Zhang, Y., Kim, S. J., Zhang, H., & Tsung, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00270-9

A Host Enzyme Reduces Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) by Inactivating Intestinal LipopolysaccharidePreprint

Wang, Z., Ojogun, N., Liu, Y., Gan, L., Xiao, Z., Feng, J., Jiang, W., Chen, Y., Zou, B., Yu, C., et al. (2025) · eLife · doi:10.7554/elife.100731.2

Hepatocyte reporter cells and integrated metabolomic and transcriptomic analyses reveal insights into hepatocyte changes in offspring of pregnancies with obesity

Kozlovich, S. Y., Pan, A. Y., McIntosh, J. J., Palatnik, A., Jia, S., Hessner, M. J., & Nghiem‐Rao, T. H. (2025) · Scientific Reports · doi:10.1038/s41598-025-10808-2

Sarcopenia as a risk factor for nonalcoholic fatty liver disease and liver fibrosis: an updated systematic review and meta-analysis

Zuo, X., Chen, D., Kang, Y., Hu, X., Zhang, Y., Tang, K., Shi, J., Li, T., & Shangguan, W. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1726600 · Cited by 1

Personalized Optimal Fat Intake for Glycemic Health: Evidence of a U‐Shaped Association and Heterogeneity From NHANES

Huang, X., Wu, M., & Huang, B. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/3991280

Notch1-Gli1 Axis Reprograms Macrophage Polarization and Promotes Hepatic Inflammation and Fibrosis in Metabolic Dysfunction–Associated Steatohepatitis

Chen, H., Yang, M., Tu, X., Li, J., Li, C., & Xia, J. (2026) · American Journal Of Pathology · doi:10.1016/j.ajpath.2026.03.001

TRIM25 promotes epithelial-mesenchymal transition of lens epithelial cells by mediating the degradation of PCBP1 to activate the Notch signaling pathway

Liu, Y., Huang, Y., Chen, A., Han, L., Bian, L., Xu, X., & Li, Y. (2026) · Experimental Eye Research · doi:10.1016/j.exer.2026.111072

Exploring the effect and mechanism of Ganoderma lucidum Polysaccharides on improving Paediatric MASLD based on network pharmacology and animal experimentPreprint

Jiang, T., Zheng, X., Ouyang, W., & Li, S. (2026) · Research Square · doi:10.21203/rs.3.rs-8597333/v1

Unleashing innovative cross-organ fibrosis therapies by harnessing the omics revolution

Lebeaupin, C., Donahue, K. L., Dower, K., Wynn, T. A., Hart, K. M., & Fabre, T. (2026) · JCI Insight · doi:10.1172/jci.insight.200155

Pathological α-synuclein propagation via the gut-liver axis induces liver injury in gut-origin Parkinson's disease mouse models

Hu, R., Wu, J., Song, Y., Tao, Y., Tan, L., Ma, X.-Y., Xia, Y.-M., Nie, X., Li, T., Li, M.-A., et al. (2026) · Experimental Neurology · doi:10.1016/j.expneurol.2026.115965

High-sucrose diet induces MMP-9 activation and collagen deposition via oxidative stress in Swiss mice liver

Passos, M. A., Silva, J. L., Leite, T. C. R., de Deus, I. J., Baleeiro, R. D. S., Gomes, R. D. F. M., de Lima, W. G., Ceron, C. S., & Paula-Gomes, S. (2026) · Histochemistry and Cell Biology · doi:10.1007/s00418-026-02523-4

Mechanotransduction Pathways in Liver Fibrosis: a Comprehensive Narrative Review

Jehangir, M., kashmiri, K., Tayyab, M., Kakhramonov, R., & Alvi, A. D. (2026) · Letters in Applied NanoBioScience · doi:10.33263/lianbs152.083

The Gut–Liver Axis in Metabolic Dysfunction–Associated Steatotic Liver Disease and Associated Hepatocellular Carcinoma

Huai, Q., Li, X., Wang, H., & Yin, S. (2026) · American Journal Of Pathology · doi:10.1016/j.ajpath.2026.09.004

siRNA therapeutics for metabolic dysfunction-associated Steatohepatitis: Targets, delivery, clinical evidence, and translational challenges

Guo, Y., & Yao, Q. (2026) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2026.102817

Context-dependent protective and pathogenic functions of YTHDF1 in MASLD and hepatocellular carcinoma: Mechanisms and design of therapeutics

Ao, S., & Wang, Y. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118550

Notch signaling regulates corpus cavernosum fibroblast function via FLNA-associated cell adhesion

Han, Z., Xu, J., Li, Z., Xu, Y., Chen, Y., Hu, H., Zeng, H., Wang, C., Zheng, X., Yin, Y., et al. (2026) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2026.151579

Hepatocyte‐Centered Regulation of MASH Fibrosis: From Animal Models to Molecular Mechanisms and Targeted Therapies

Jung, E. J., & Wang, X. (2026) · iNew Medicine · doi:10.1002/inm3.70097

Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis

Zhu, C., Kim, K., Wang, X., Bartolome, A., Salomao, M., Dongiovanni, P., Meroni, M., Graham, M. J., Yates, K. P., Diehl, A. M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat0344 · Cited by 250

Hepatocyte-targeted siTAZ therapy lowers liver fibrosis in NASH diet-fed chimeric mice with hepatocyte-humanized livers

Wang, X., Moore, M. P., Shi, H., Miyata, Y., Donnelly, S. K., Radiloff, D. R., & Tabas, I. (2023) · Molecular Therapy Methods & Clinical Development · doi:10.1016/j.omtm.2023.101165 · Cited by 21

Notch and Nonalcoholic Fatty Liver and Fibrosis

Romeo, S. (2019) · New England Journal of Medicine · doi:10.1056/nejmcibr1815636 · Cited by 49

Hepatocyte Notch in non-alcoholic steatohepatitis (NASH)-associated liver fibrosis and cancer

Zhu, C. (2019) · doi:10.7916/d8-877b-v389

Jagged-1 signalling is required in liver fibrogensis

Weng, H., Liu, Y., Ilkavets, I., Shen, H., Zimmer, V., Lammert, F., Mueller, A. J., Herweck, F., Stump, C., Mertens, P., et al. (2011) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0030-1269508